Cytek Biosciences (CTKB) Work In Process (2020 - 2026)

Cytek Biosciences has reported Work In Process for 7 years, with the latest figure at $16.3 million in Q1 2026.

• For the quarter ending Q1 2026, Work In Process rose 155.62% year-over-year to $16.3 million; the trailing twelve-month figure through Mar 2026 stood at $16.3 million (up 155.62% YoY), and the FY2025 full-year result was $16.5 million, up 154.79% from the prior year.
• Work In Process for Q1 2026 stood at $16.3 million, down from $16.5 million in the prior quarter.
• The five-year high for Work In Process was $16.5 million in Q4 2025, with the low at $1.5 million in Q1 2022.
• Historically, Work In Process has averaged $7.4 million across 5 years, with a median of $6.3 million in 2024.
• Annual changes were most pronounced in 2023 — Work In Process jumped 201.39% — and 2024, when it tumbled 48.56%.
• Cytek Biosciences' Work In Process stood at $4.9 million in 2022, then surged by 113.48% to $10.5 million in 2023, then plunged by 37.94% to $6.5 million in 2024, then surged by 154.79% to $16.5 million in 2025, then retreated by 1.16% to $16.3 million in 2026.
• The last three Work In Process figures came in at $16.3 million (Q1 2026), $16.5 million (Q4 2025), and $6.7 million (Q3 2025), per Business Quant data.